🇮🇳 India Stock Screener ← Switch market ⚡ HerAI
Financial distress indicators · updated 2026-10-09

Lasa Supergenerics Limited — financial distress indicators

LASA — open full stock page →
HealthcareDrug Manufacturers - Specialty & Generic Mkt cap ₹26.65 CrStatements as of Mar 2026 Flows: FY Mar 2026
82VERY WEAK
Distress score / 100
Statistical model output from public data — not an allegation of insolvency or default. Methodology

Financial-health summary

Lasa Supergenerics Limited's reported numbers place it in the 'Very weak' financial-health band (distress score 82/100). The main indicators are operating profit does not cover interest, severe working-capital shortfall and losses in each of the last 3 years. Independently, the Ohlson accounting model puts its 1-year failure probability at 89% and the market-implied (Merton) default probability is 2.8%. In its favour: high insider/promoter ownership (55%) aligns management with survival.

0.62
Current ratio
-34.66×
Interest cover
—
Debt / EBITDA
113 mo
Cash runway
89%
Ohlson 1-yr PD
2.8%
Merton 1-yr PD
₹69.67 L
Cash & ST investments
₹9.75 Cr
Total debt
-58%
From 52-week high

Stress by dimension

Share price — last 12 months

Indicators behind the score

Each red flag shows the evidence from the company’s own filings and the financial or legal principle behind it. Points add to the 0–100 score.

Operating profit does not cover interest+15
Solvency

Interest coverage (EBIT / interest) is -34.66×.

When EBIT < interest, debt service is funded from cash reserves or new borrowing — the classic precursor to payment default and covenant breach.

Severe working-capital shortfall+12
Liquidity

Current ratio is 0.62 (current assets cover 62% of near-term obligations).

Cash-flow insolvency test: inability to pay debts as they fall due is the trigger for both U.S. involuntary petitions and Indian IBC default.

Losses in each of the last 3 years+12
Profitability

Net income negative in 3 of 3 fiscal years.

Persistent losses erode equity and the capacity to absorb shocks.

Revenue collapse+12
Sales Trend

Revenue changed -82% year over year.

A >30% sales drop typically breaches leverage covenants and starves fixed-cost coverage.

Operations consume cash+10
Cash Flow

Operating cash flow negative in 2 of the last 3 years.

A business that cannot fund itself from operations depends on external capital to survive.

Ohlson O-score signals likely failure+10
Market Signal

O-score 2.08 → model probability 89%.

Ohlson (1980) logit model of 1-year corporate failure; O > 0 (p > 50%) is the original failure cut-off.

Near-term debt exceeds cash+6
Liquidity

Short-term debt is 14.0× cash on hand.

Maturity wall: debt due within a year must be refinanced, which is the most common proximate cause of filings.

Operating-margin collapse+5
Profitability

Operating margin fell from -8% to -53% in two years.

Sharp margin compression signals loss of pricing power or cost control.

Revenue vs net income

Cash generation

Debt vs cash vs equity

✅ Mitigating factors

  • High insider/promoter ownership (55%) aligns management with survival.

📰 Recent news scan

  • No recent headlines cached for this company.

Frequently asked questions

What do Lasa Supergenerics Limited's financial-health indicators show?

As of 2026-10-09, Lasa Supergenerics Limited's public financial data places it in the 'Very weak' band with a distress score of 82/100, driven by operating profit does not cover interest, severe working-capital shortfall and losses in each of the last 3 years. This is a statistical screen of reported numbers — it does not mean the company is insolvent, has defaulted or will enter insolvency proceedings.

What is Lasa Supergenerics Limited's financial distress score?

82/100 ('Very weak'). Ohlson O-score 2.08 (model 1-year failure probability 89%). Merton distance-to-default 1.9 σ (model default probability 2.8%).

What works in Lasa Supergenerics Limited's favour?

High insider/promoter ownership (55%) aligns management with survival.

How are shareholders treated if a company enters insolvency?

Under the IBC the Committee of Creditors controls the resolution; the §53 waterfall pays secured creditors and workers first and equity last. In most resolution plans existing shareholders are wiped out or left with a token stake, and the company may be delisted.

Other Pharma & Biotech companies with distress indicators

All Pharma & Biotech companies with distress indicators →

Methodology

Score = capped sum of rule-based red flags across seven dimensions (liquidity, solvency, profitability, cash flow, sales trend, market signal, news). Ohlson O-score (1980) gives an accounting-based 1-year failure probability; Merton distance-to-default (Bharath & Shumway 2008) gives a market-implied probability. Financial institutions use a capital-based rule set. Recalculated every trading day from the latest filings, prices and news.

Not a prediction of default or insolvency. This page summarises statistical risk indicators from public data. It does not allege insolvency, default or wrongdoing, and the company may have resources or plans not reflected here (undrawn credit lines, asset sales, parent support, recent capital raises). Verify with the company’s filings (exchange disclosures, annual report). Not investment or legal advice.